Formulation and Drug Delivery, Solid Dosage

Cycle and Aprecia will use Aprecia's 3DP Technology to improve rare disease drug formulations.

Orbis Biosciences’ Optimµm Platform delivers microparticulate dosage forms with controlled-release and taste-masked properties in a single manufacturing step.

Softgel capsules are a popular dosage form among patients but they also provide a number of manufacturing benefits over liquid-filled hardgel capsules.

Modified-release lipid-based formulations in softgel capsules can address physiochemical and pharmacokinetic challenges posed by drug compounds.

As part of Recipharm’s ongoing initiative to improve profitability and competitiveness, a decision has been made to end operations in Stockholm and Höganäs.

Ralph Gosden, head of product development at Catalent’s Swindon, United Kingdom site, explains the opportunities of orally disintegrating tablets as a patient-centric dosage form.

Pharmaceutical companies are increasingly adopting patient-centric formulation development to ensure that drug products adequately meet the needs of end-users in all target patient populations.

Taste masking increases drug acceptability and medication adherence in pediatric, geriatric, and other special patient populations.

Model-based formulation and technology selection methodologies facilitate rapid product development.

Capsules offer certain benefits over tablets for oral-solid dosage drugs, and several types of capsules are available.

EMA and FDA guidance encourages design of drug products to improve patient compliance.

Capsule filling is a complex process, and the product to be encapsulated must be well developed to ensure mass uniformity.

A recent survey examines the industry's views on the chief challenges and technologies in drug delivery and formulation development.

We're all familiar with traditional pills and medicines, but how about medicated chewing gum? Marc Ribe of Cafosa Gum explains how APIs can be incorporated into a novel dosage form that can aid patient compliance.

The authors examine an oral-absorption-enhancement technology based on surface-active materials to increase apical membrane fluidity in vitro.

The authors describe the various available technologies used in orally disintegrating tablets.

The authors review various oral drug delivery systems that have been explored to increase patient compliance for insulin.

The authors review the solution and powder properties of polyethylene oxide and its various applications in hydrogels and hydrophilic matrix systems.

The authors investigate whether an extrusion-spheronization proces can be used to develop a matrix-based, controlled-release formulation for a highly water-soluble drug.

The study presented in this article used a controlled-porosity osmotic pump, which was prepared in the form of a bilayered tablet containing a drug compartment and an osmogen layer for the delayed release of diltiazem HCI.

Insulin is one of the most popular proteins to be studied for oral delivery. The authors review the current status of the development strategies of insulin drug delivery systems, the various challenges associated with these systems, and how these challenges may be overcome.